dc.contributor.author | Sjøli, Stian | |
dc.contributor.author | Nuti, Elisa | |
dc.contributor.author | Camodeca, Caterina | |
dc.contributor.author | Bilto, Irina | |
dc.contributor.author | Rossello, Armando | |
dc.contributor.author | Winberg, Jan-Olof | |
dc.contributor.author | Sylte, Ingebrigt | |
dc.contributor.author | Adekoya, Olayiwola | |
dc.date.accessioned | 2017-03-15T11:27:14Z | |
dc.date.available | 2017-03-15T11:27:14Z | |
dc.date.issued | 2015-11-28 | |
dc.description.abstract | Enzymes of the M4 family of zinc-metalloproteinases are virulence factors secreted from gram-positive or gram-negative bacteria, and putative drug targets in the treatment of bacterial infections. In order to have a therapeutic value such inhibitors should not interfere with endogenous zinc-metalloproteinases. In the present study we have synthesised a series of hydroxamate derivatives and validated the compounds as inhibitors of the M4 enzymes thermolysin and pseudolysin, and the endogenous metalloproteinases ADAM-17, MMP-2 and MMP-9 using experimental binding studies and molecular modelling. In general, the compounds are stronger inhibitors of the MMPs than of the M4 enzymes, however, an interesting exception is LM2. The compounds bound stronger to pseudolysin than to thermolysin, and the molecular modelling studies showed that occupation of the S2’ subpocket by an aromatic group is favourable for strong interactions with pseudolysin. | en_US |
dc.description.sponsorship | This study was supported by fundings from the Italian Ministry of Education, University and Research (MIUR, PRIN 2007, 2007JERJPC_005) and from the University of Pisa (Fondi di Ateneo 2009, to A. R.) | en_US |
dc.description | Manuscript. Published version available in <a href=http://dx.doi.org/10.1016/j.ejmech.2015.11.019>European Journal of Medicinal Chemistry, Vol. 108, 27 January 2016, pp 141–153</a> | en_US |
dc.identifier.citation | Sjøli, S et al. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors. European Journal of Medicinal Chemistry. 2016;108:141-153 | en_US |
dc.identifier.cristinID | FRIDAID 1421544 | |
dc.identifier.doi | 10.1016/j.ejmech.2015.11.019 | |
dc.identifier.issn | 0223-5234 | |
dc.identifier.issn | 1768-3254 | |
dc.identifier.uri | https://hdl.handle.net/10037/10690 | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.journal | European Journal of Medicinal Chemistry | |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Mathematics and natural science: 400::Chemistry: 440 | en_US |
dc.subject | VDP::Matematikk og Naturvitenskap: 400::Kjemi: 440 | en_US |
dc.subject | VDP::Medisinske Fag: 700 | en_US |
dc.subject | VDP::Medical disciplines: 700 | en_US |
dc.title | Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |